Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 670

1.

Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ.

Br J Haematol. 2018 Jul 13. doi: 10.1111/bjh.15492. [Epub ahead of print]

PMID:
30004111
2.

Maintenance of CD4 T cell fitness through regulation of Foxo1.

Newton RH, Shrestha S, Sullivan JM, Yates KB, Compeer EB, Ron-Harel N, Blazar BR, Bensinger SJ, Haining WN, Dustin ML, Campbell DJ, Chi H, Turka LA.

Nat Immunol. 2018 Jul 9. doi: 10.1038/s41590-018-0157-4. [Epub ahead of print]

PMID:
29988091
3.

The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells.

Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC.

Nature. 2018 Jul;559(7713):264-268. doi: 10.1038/s41586-018-0282-0. Epub 2018 Jul 4.

PMID:
29973721
4.

Despite high levels of expression in thymic epithelial cells, miR-181a1 and miR-181b1 are not required for thymic development.

Stefanski HE, Xing Y, Taylor PA, Maio S, Henao-Meija J, Williams A, Flavell RA, Hollander GA, Blazar BR.

PLoS One. 2018 Jun 27;13(6):e0198871. doi: 10.1371/journal.pone.0198871. eCollection 2018.

5.

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS.

Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.

6.

Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Habtetsion T, Ding ZC, Pi W, Li T, Lu C, Chen T, Xi C, Spartz H, Liu K, Hao Z, Mivechi N, Huo Y, Blazar BR, Munn DH, Zhou G.

Cell Metab. 2018 May 30. pii: S1550-4131(18)30319-X. doi: 10.1016/j.cmet.2018.05.012. [Epub ahead of print]

PMID:
29887396
7.

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS.

Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.

PMID:
29784636
8.

Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, Tolar J, Osborn MJ, Blazar BR.

Mol Ther. 2018 Jun 6;26(6):1423-1434. doi: 10.1016/j.ymthe.2018.04.006. Epub 2018 Apr 7.

PMID:
29735365
9.

Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis.

Owen DL, Mahmud SA, Vang KB, Kelly RM, Blazar BR, Smith KA, Farrar MA.

J Immunol. 2018 Jun 15;200(12):3926-3933. doi: 10.4049/jimmunol.1800097. Epub 2018 May 4.

PMID:
29728511
10.

Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Blazar BR, MacDonald KPA, Hill GR.

Blood. 2018 Jun 14;131(24):2651-2660. doi: 10.1182/blood-2017-11-785865. Epub 2018 May 4. Review.

PMID:
29728401
11.

MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function.

Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R, Ranganathan P.

J Immunol. 2018 Jun 15;200(12):4170-4179. doi: 10.4049/jimmunol.1701465. Epub 2018 May 2.

PMID:
29720426
12.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR.

Blood Adv. 2018 Apr 24;2(8):909-922. doi: 10.1182/bloodadvances.2017014464.

13.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
14.

A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.

Stefanski HE, Jonart L, Goren E, Mulé JJ, Blazar BR.

PLoS One. 2018 Apr 4;13(4):e0193461. doi: 10.1371/journal.pone.0193461. eCollection 2018.

15.

CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression.

Osborn MJ, Lees CJ, McElroy AN, Merkel SC, Eide CR, Mathews W, Feser CJ, Tschann M, McElmury RT, Webber BR, Kim CJ, Blazar BR, Tolar J.

Int J Mol Sci. 2018 Mar 22;19(4). pii: E946. doi: 10.3390/ijms19040946.

16.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, Yu A, Zheng H, Furlan SN, Hunt DJ, Hoglund V, Finney O, Brakke H, Blazar BR, Berger C, Riddell SR, Gardner R, Kean LS, Jensen MC.

Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.

PMID:
29563103
17.

MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.

Wu Y, Schutt S, Paz K, Zhang M, Flynn RP, Bastian D, Sofi MH, Nguyen H, Dai M, Liu C, Chang YJ, Blazar BR, Yu XZ.

Blood. 2018 Apr 26;131(17):1974-1986. doi: 10.1182/blood-2017-06-789321. Epub 2018 Mar 12.

PMID:
29530952
18.

Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Miller JS, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2018 Mar 7. doi: 10.1038/s41409-018-0127-3. [Epub ahead of print] No abstract available.

PMID:
29515246
19.

Correction: B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells.

Zhang R, Sage PT, Finn K, Huynh A, Blazar BR, Marangoni F, Mempel TR, Sharpe AH, Turka LA.

J Immunol. 2018 Apr 1;200(7):2505-2506. doi: 10.4049/jimmunol.1800150. Epub 2018 Feb 23. No abstract available.

PMID:
29475985
20.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

PMID:
29467301
21.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

PMID:
29463563
22.

Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.

Hülsdünker J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, Follo M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lämmermann T, Blaser MJ, Fife BT, Blazar BR, Beilhack A, Hill GR, Häcker G, Zeiser R.

Blood. 2018 Apr 19;131(16):1858-1869. doi: 10.1182/blood-2017-10-812891. Epub 2018 Feb 20.

PMID:
29463561
23.

miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg).

Lu Y, Gao J, Zhang S, Gu J, Lu H, Xia Y, Zhu Q, Qian X, Zhang F, Zhang C, Shen H, Hippen KL, Blazar BR, Lu L, Wang X.

Cell Death Dis. 2018 Feb 19;9(3):290. doi: 10.1038/s41419-018-0298-2.

24.

Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease.

Hippen KL, Loschi M, Nicholls J, MacDonald KPA, Blazar BR.

Front Immunol. 2018 Jan 31;9:57. doi: 10.3389/fimmu.2018.00057. eCollection 2018. Review.

25.

B-cell targeting in chronic graft-versus-host disease.

Zeiser R, Sarantopoulos S, Blazar BR.

Blood. 2018 Mar 29;131(13):1399-1405. doi: 10.1182/blood-2017-11-784017. Epub 2018 Feb 1. Review.

PMID:
29437591
26.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

PMID:
29431743
27.

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect.

Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, Geller MA, Tolar J, Blazar BR, Miller JS.

JCI Insight. 2018 Feb 8;3(3). pii: 96219. doi: 10.1172/jci.insight.96219. [Epub ahead of print]

28.

Acute Graft-versus-Host Disease.

Zeiser R, Blazar BR.

N Engl J Med. 2018 Feb 8;378(6):586. doi: 10.1056/NEJMc1716969. No abstract available.

29.

Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.

Du J, Flynn R, Paz K, Ren HG, Ogata Y, Zhang Q, Gafken PR, Storer BE, Roy NH, Burkhardt JK, Mathews W, Tolar J, Lee SJ, Blazar BR, Paczesny S.

Blood. 2018 Apr 12;131(15):1743-1754. doi: 10.1182/blood-2017-08-800623. Epub 2018 Jan 18.

PMID:
29348127
30.

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors.

Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, Bronte V, Wolchok JD, Blazar BR, Munn DH.

Immunity. 2018 Jan 16;48(1):91-106.e6. doi: 10.1016/j.immuni.2017.12.014.

PMID:
29343444
31.

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.

Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP 3rd.

Haematologica. 2018 Mar;103(3):522-530. doi: 10.3324/haematol.2017.176859. Epub 2018 Jan 11.

32.

Cadherin 17 mutation associated with leaky severe combined immune deficiency is corrected by HSCT.

Smith AR, Rota IA, Maio S, Massaad MJ, Lund TC, Notarangelo LD, Holländer GA, Blazar BR.

Blood Adv. 2017 Oct 23;1(23):2083-2087. doi: 10.1182/bloodadvances.2017010926. eCollection 2017 Oct 24.

33.

Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.

Zeiser R, Blazar BR.

N Engl J Med. 2017 Dec 28;377(26):2565-2579. doi: 10.1056/NEJMra1703472. Review. No abstract available.

PMID:
29281578
34.

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, Curtsinger JM, Burns L, Weisdorf DJ, Miller JS.

Cancer Immunol Immunother. 2018 Mar;67(3):483-494. doi: 10.1007/s00262-017-2100-1. Epub 2017 Dec 7.

PMID:
29218366
35.

Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.

Williams RL, Cooley S, Bachanova V, Blazar BR, Weisdorf DJ, Miller JS, Verneris MR.

Biol Blood Marrow Transplant. 2018 Mar;24(3):618-622. doi: 10.1016/j.bbmt.2017.11.022. Epub 2017 Nov 29.

PMID:
29197679
36.

Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Zeiser R, Blazar BR.

N Engl J Med. 2017 Nov 30;377(22):2167-2179. doi: 10.1056/NEJMra1609337. Review. No abstract available.

PMID:
29171820
37.

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J.

Blood. 2017 Dec 28;130(26):2889-2899. doi: 10.1182/blood-2017-08-801001. Epub 2017 Nov 14.

PMID:
29138220
38.

B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells.

Zhang R, Sage PT, Finn K, Huynh A, Blazar BR, Marangoni F, Mempel TR, Sharpe AH, Turka LA.

J Immunol. 2017 Dec 15;199(12):3972-3980. doi: 10.4049/jimmunol.1700409. Epub 2017 Nov 1. Erratum in: J Immunol. 2018 Feb 23;:.

PMID:
29093061
39.

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG.

Bone Marrow Transplant. 2018 Jan;53(1):64-68. doi: 10.1038/bmt.2017.236. Epub 2017 Oct 23.

40.

A critical role for donor-derived IL-22 in cutaneous chronic GVHD.

Gartlan KH, Bommiasamy H, Paz K, Wilkinson AN, Owen M, Reichenbach DK, Banovic T, Wehner K, Buchanan F, Varelias A, Kuns RD, Chang K, Fedoriw Y, Shea T, Coghill J, Zaiken M, Plank MW, Foster PS, Clouston AD, Blazar BR, Serody JS, Hill GR.

Am J Transplant. 2018 Apr;18(4):810-820. doi: 10.1111/ajt.14513. Epub 2017 Oct 24.

PMID:
28941323
41.

Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.

Tkachev V, Furlan SN, Watkins B, Hunt DJ, Zheng HB, Panoskaltsis-Mortari A, Betz K, Brown M, Schell JB, Zeleski K, Yu A, Kirby I, Cooley S, Miller JS, Blazar BR, Casson D, Bland-Ward P, Kean LS.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaan3085. doi: 10.1126/scitranslmed.aan3085.

PMID:
28931653
42.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S.

Blood. 2017 Nov 23;130(21):2243-2250. doi: 10.1182/blood-2017-07-793786. Epub 2017 Sep 18.

PMID:
28924018
43.

An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Poe JC, Jia W, Su H, Anand S, Rose JJ, Tata PV, Suthers AN, Jones CD, Kuan PF, Vincent BG, Serody JS, Horwitz ME, Ho VT, Pavletic SZ, Hakim FT, Owzar K, Zhang D, Blazar BR, Siebel CW, Chao NJ, Maillard I, Sarantopoulos S.

Blood. 2017 Nov 9;130(19):2131-2145. doi: 10.1182/blood-2017-05-782466. Epub 2017 Aug 29.

PMID:
28851699
44.

Increased Effector Memory Insulin-Specific CD4+ T Cells Correlate With Insulin Autoantibodies in Patients With Recent-Onset Type 1 Diabetes.

Spanier JA, Sahli NL, Wilson JC, Martinov T, Dileepan T, Burrack AL, Finger EB, Blazar BR, Michels AW, Moran A, Jenkins MK, Fife BT.

Diabetes. 2017 Dec;66(12):3051-3060. doi: 10.2337/db17-0666. Epub 2017 Aug 25.

45.

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.

Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P, McCullar V, Howard P, Sarhan D, Taras E, Schlums H, Abbot S, Shoemaker D, Bryceson YT, Blazar BR, Wolchko S, Cooley S, Miller JS.

Cancer Res. 2017 Oct 15;77(20):5664-5675. doi: 10.1158/0008-5472.CAN-17-0799. Epub 2017 Aug 8.

PMID:
28790065
46.

Eomesodermin promotes the development of type 1 regulatory T (TR1) cells.

Zhang P, Lee JS, Gartlan KH, Schuster IS, Comerford I, Varelias A, Ullah MA, Vuckovic S, Koyama M, Kuns RD, Locke KR, Beckett KJ, Olver SD, Samson LD, Montes de Oca M, de Labastida Rivera F, Clouston AD, Belz GT, Blazar BR, MacDonald KP, McColl SR, Thomas R, Engwerda CR, Degli-Esposti MA, Kallies A, Tey SK, Hill GR.

Sci Immunol. 2017 Apr 7;2(10). pii: eaah7152. doi: 10.1126/sciimmunol.aah7152.

47.

Cytokine mediators of chronic graft-versus-host disease.

MacDonald KP, Blazar BR, Hill GR.

J Clin Invest. 2017 Jun 30;127(7):2452-2463. doi: 10.1172/JCI90593. Epub 2017 Jun 30. Review.

48.

Human in vitro-induced regulatory T cells display Dlgh1dependent and PKC-θ restrained suppressive activity.

Zanin-Zhorov A, Kumari S, Hippen KL, Merkel SC, MacMillan ML, Blazar BR, Dustin ML.

Sci Rep. 2017 Jun 26;7(1):4258. doi: 10.1038/s41598-017-04053-5.

49.

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR.

JCI Insight. 2017 Jun 15;2(12). pii: 92111. doi: 10.1172/jci.insight.92111. [Epub ahead of print]

50.

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A.

Bone Marrow Transplant. 2017 Sep;52(9):1300-1303. doi: 10.1038/bmt.2017.89. Epub 2017 Jun 5.

PMID:
28581470

Supplemental Content

Loading ...
Support Center